Holen Sie sich die Stockscreener-App
6.75
0.45%
0.03
Handel nachbörslich:
6.81
0.06
+0.89%
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst: The $700 Million Pivot From Oral Convenience To Injectable - Seeking Alpha
Astria stockholders approve acquisition by BioCryst - Investing.com Nigeria
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria stockholders vote to approve acquisition by BioCryst - marketscreener.com
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
BioCryst: A Changed And Interesting Thesis For 2026 (NASDAQ:BCRX) - Seeking Alpha
Campbell & CO Investment Adviser LLC Decreases Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Does BioCryst (BCRX) 2026 Revenue Guidance Reframe the ORLADEYO Growth Story for Investors? - simplywall.st
A Look At BioCryst Pharmaceuticals (BCRX) Valuation After Its New 2026 Revenue Guidance - Sahm
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 5.8%What's Next? - MarketBeat
Stock Recap: What is The OLB Group Incs P E ratio telling us2025 Macro Impact & Smart Money Movement Alerts - baoquankhu1.vn
(BCRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Aug Volume: Why BioCryst Pharmaceuticals Inc stock could outperform in 2025 - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc stock outperform growth indexes2025 Momentum Check & Reliable Momentum Entry Alerts - Bộ Nội Vụ
BioCryst stock holds steady as Cantor Fitzgerald reaffirms Overweight rating By Investing.com - Investing.com UK
Citizens reiterates Market Outperform rating on BioCryst Pharma stock By Investing.com - Investing.com Canada
BioCryst reports $563 million in ORLADEYO revenue for 2025 By Investing.com - Investing.com Nigeria
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - MarketBeat
Investment Report: Why BioCryst Pharmaceuticals Inc. stock is in analyst buy zoneMarket Sentiment Review & Weekly Watchlist of Top Performers - Bộ Nội Vụ
Portfolio Update: Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsWeekly Investment Report & AI Enhanced Trading Signals - Bộ Nội Vụ
BCRX: ORLADEYO growth, Astria acquisition, and pipeline advances drive rare disease expansion - TradingView — Track All Markets
BioCryst reports $563 million in ORLADEYO revenue for 2025 - Investing.com
BCRX Forecasts FY26 ORLADEYO Revenue in Range of $625M-$645M - GuruFocus
BCRX: ORLADEYO Sees Strong Revenue Growth in Q4 2025 - GuruFocus
(BCRX) BioCryst Expects 2026 Revenue Range $635M to $660M, vs. FactSet Est of $660.5M - marketscreener.com
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - The Manila Times
Once-daily pill for HAE patients now brings in $601M a year - Stock Titan
BioCryst Stock Tumbles On Astria Buyout, But Analysts Stay Bullish — Retail Cheers The Move As Long-Term Play - MSN
Published on: 2026-01-10 14:45:46 - Улправда
FDA approves seven NMEs in December - biocentury.com
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Volatility - Sahm
BioCryst Pharmaceuticals, Inc.Common Stock (NQ: BCRX - FinancialContent
BioCryst to buy Astria Therapeutics for $13 per share (update) - MSN
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack - Investing.com Nigeria
BioCryst Pharmaceuticals raises US price of Orladeyo to $48,487.92 per pack By Investing.com - Investing.com South Africa
BioCryst Raises Price of Key ORLADEYO Treatment - TipRanks
BioCryst Pharmaceuticals Increases ORLADEYO® Price - TradingView — Track All Markets
Is BioCryst Pharmaceuticals Inc. stock oversold or undervalued2025 Trading Recap & AI Forecasted Entry and Exit Points - ulpravda.ru
How BioCryst Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - Улправда
Will BioCryst Pharmaceuticals Inc. stock benefit from upcoming earnings reportsGap Down & Free Verified High Yield Trade Plans - ulpravda.ru
CEO Moves: Will BioCryst Pharmaceuticals Inc. stock deliver long term returnsPortfolio Update Report & Expert Verified Movement Alerts - Улправда
HC Wainwright lifts PT on BioCryst Pharmaceuticals (BCRX) to $32 from $30 - MSN
A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction - Yahoo Finance
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $15, Keeps Outperform Rating - marketscreener.com
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - The Malaysian Reserve
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Inves - GuruFocus
BioCryst reports inducement grants under Nasdaq listing rule - MSN
Why are retail traders going gaga over BioCryst Pharma stock today? - MSN
BioCryst Pharmaceuticals Q2 2025 Earnings Preview - MSN
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A Look At 178% Potential Upside - DirectorsTalk Interviews
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Liquidity Mapping Around (BCRX) Price Events - Stock Traders Daily
Will BioCryst Pharmaceuticals Inc. stock beat EPS estimatesRisk Management Strategies & Invest Smarter With Signals - bollywoodhelpline.com
3.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):